DelveInsight’s “Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ichthyosis, historical and forecasted epidemiology as well as the Ichthyosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ichthyosis Market Forecast
Some of the key facts of the Ichthyosis Market Report:
The Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2025, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has reported additional positive interim data from its ongoing clinical study for Netherton Syndrome. The company previously shared promising results from the first subject dosed twice daily with QRX003 at the six-week midpoint. Now, Quoin has released clinical data following the full 12-week treatment period, highlighting significant improvements across all measured clinical endpoints. The observed results further support the potential efficacy of QRX003 in treating Netherton Syndrome, reinforcing its role as a promising therapeutic candidate for this rare condition.
In August 2024, Timber Pharmaceuticals Inc., a LEO Pharma company, has released findings from the randomized, double-blind 12-week phase of the ASCEND trial. The study did not demonstrate a statistically significant difference in response rates between patients treated with TMB-001 and those receiving the vehicle after 12 weeks. ASCEND is a Phase 3 clinical trial evaluating TMB-001, an investigational topical isotretinoin formulation, as a potential treatment for moderate to severe congenital ichthyosis.
In March 2024, Timber Pharmaceuticals, Inc., a subsidiary of LEO Pharma, presented preliminary findings from the ASCEND trial during a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The ASCEND trial evaluates TMB-001, an investigational polyethylene glycol (iPEG™)-based topical isotretinoin, being developed to treat moderate-to-severe X-linked and autosomal recessive congenital ichthyosis (CI). CI is a group of rare genetic keratinization disorders characterized by dry, thickened, and scaling skin. Currently, no FDA-approved treatments are available specifically for CI.
Ichthyosis affects approximately 1 in 250,000 births for the most severe forms, while milder forms like Ichthyosis vulgaris occur in about 1 in 250 to 1 in 1,000 people.
There are more than 20 different types of ichthyosis, including Ichthyosis vulgaris, X-linked ichthyosis, and Harlequin ichthyosis.
Most types are inherited in an autosomal dominant or recessive manner, while some can be acquired due to underlying conditions.
X-linked ichthyosis primarily affects males, while other forms occur in both genders.
Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Crown Laboratories, Inc, and others
Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
The Ichthyosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ichthyosis pipeline products will significantly revolutionize the Ichthyosis market dynamics.
Ichthyosis Overview
Ichthyosis is a group of rare genetic skin disorders characterized by dry, scaly, thickened, or flaky skin due to abnormal skin cell shedding and renewal. It results from mutations affecting skin barrier function, leading to excessive keratin buildup. Symptoms can range from mild dryness to severe scaling and cracking, often causing discomfort and an increased risk of infections. The condition may be present at birth or develop later in life. While there is no cure, treatment focuses on managing symptoms through moisturizing creams, keratolytic agents, and, in some cases, systemic therapies to improve skin hydration and reduce scaling.
Get a Free sample for the Ichthyosis Market Report
https://www.delveinsight.com/report-store/ichthyosis-market
Ichthyosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Ichthyosis Epidemiology Segmentation:
The Ichthyosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Ichthyosis
Prevalent Cases of Ichthyosis by severity
Gender-specific Prevalence of Ichthyosis
Diagnosed Cases of Episodic and Chronic Ichthyosis
Download the report to understand which factors are driving Ichthyosis epidemiology trends @ Ichthyosis Epidemiology Forecast
Ichthyosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ichthyosis market or expected to get launched during the study period. The analysis covers Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Ichthyosis Therapies and Key Companies
TMB-001: Timber Pharmaceuticals
KB105: Krystal Biotech
Liarozole: GSK
TMB-001: Timber Pharmcecuticals
Ustekinumab: Janssen Scientific
PAT-001: Patagonia Pharma
Isotretinoin: Timber Pharmcuticals
146-9251: Crown Laboratories, Inc
Discover more about therapies set to grab major Ichthyosis market share @ Ichthyosis Treatment Market
Ichthyosis Market Strengths
Ongoing Search for Cure – Along with clinical trials in Ichthyosis, various institute/ organization/ and groups are conducting research to find cure for this disease.
Various Organization and Foundation Support – Organizations and government level support has aided in further development of angleman syndrome treatment
Ichthyosis Market Opportunities
Lack of treatment protocols
Research funding
Biomarker research
Integrative and novel therapies
Scope of the Ichthyosis Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Ichthyosis Therapeutic Assessment: Ichthyosis current marketed and Ichthyosis emerging therapies
Ichthyosis Market Dynamics: Ichthyosis market drivers and Ichthyosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Ichthyosis Unmet Needs, KOL’s views, Analyst’s views, Ichthyosis Market Access and Reimbursement
To know more about Ichthyosis companies working in the treatment market, visit @ Ichthyosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Ichthyosis Market Report Introduction
2. Executive Summary for Ichthyosis
3. SWOT analysis of Ichthyosis
4. Ichthyosis Patient Share (%) Overview at a Glance
5. Ichthyosis Market Overview at a Glance
6. Ichthyosis Disease Background and Overview
7. Ichthyosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ichthyosis
9. Ichthyosis Current Treatment and Medical Practices
10. Ichthyosis Unmet Needs
11. Ichthyosis Emerging Therapies
12. Ichthyosis Market Outlook
13. Country-Wise Ichthyosis Market Analysis (2019–2032)
14. Ichthyosis Market Access and Reimbursement of Therapies
15. Ichthyosis Market Drivers
16. Ichthyosis Market Barriers
17. Ichthyosis Appendix
18. Ichthyosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
